An open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the effect of EP395 on systemic exposure of midazolam and digoxin (Part B)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506345-34-00

Acronym

EP395-004

Enrollment

Registered

2023-09-26

Start date

2023-10-23

Completion date

2024-01-02

Last updated

2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026